UPDATE: Medtronic wins Health Canada license for drug-coated balloon, touts Japanese data

Medtronic (NYSE:MDT) touted 1 year data from the In.Pact SFA Japan trial of its drug-coated balloon compared to plain balloon angioplasty. The company also said today it won regulatory approval in Canada for its In.Pact Admiral DCB in patients with peripheral artery disease in the upper leg. The trial enrolled 100 patients, 68 of whom were treated with the drug-coated balloon and 32 with plain balloon angioplasty. Primary patency, or restoration of adequate blood flow through the treated segment of diseased artery, was 89.2% for the DCB group and 48.4% for the control group at 12-months follow-up. Get the full story at our sister site, Drug Delivery Business News. The post UPDATE: Medtronic wins Health Canada license for drug-coated balloon, touts Japanese data appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Vascular Wall Street Beat Medtronic Source Type: news